Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05370196 · ClinicalTrials.gov registry record · NA
Synthetic Male Condom Slippage-Breakage Study
A NA study of Sexually Transmitted Diseases and Contraceptive, sponsored by Church & Dwight Company.
- Completed
- Registry status
- NA
- Development phase
- 600
- Enrollment target
- 2
- Study locations
NCT05370196: Completed NA study of Sexually Transmitted Diseases and Contraceptive, sponsored by Church & Dwight Company.
NCT05370196 is a NA study of Sexually Transmitted Diseases and Contraceptive that has completed, run by Church & Dwight Company. The registered enrollment target is 600 participants, below the 1,234-participant average among 35 other Sexually Transmitted Diseases trials with a reported enrollment target (51% lower). The trial reports 2 study locations across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05370196, a NA study of Sexually Transmitted Diseases and Contraceptive, has completed, sponsored by Church & Dwight Company.
- COMPLETED
- Registry status
- NA
- Development phase
- 600 participants
- Enrollment target
- 2
- Study locations
Study Summary
This is a multi-site, double-blind, crossover, randomized phase II study to evaluate the functional performance of a synthetic male condom as compared to a marketed latex condom.
Primary Outcome
The number of condoms that broke or slipped completely off the penis during intercourse or withdrawal divided by the number of condoms used for vaginal intercourse.
Conditions Studied
Interventions
- DEVICE Test Product
- DEVICE Control Product
Study Locations (2)
California
- Essential Access Health - Berkeley
- Essential Access Health - Los Angeles
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 600 participants |
| Start Date | 2022-06-10 |
| Est. Completion | 2023-05-12 |
| Phase | NA |
What the finished NCT05370196 record still lists
NCT05370196 is an interventional study that assigns participants to a tested intervention. The registered 600 participants enrollment target is mid-sized for trials with a published cap, below the 1,234-participant average among 35 other Sexually Transmitted Diseases trials with a reported enrollment target (51% lower).
The record links to 2 conditions, with Sexually Transmitted Diseases appearing as the primary indexed condition, and to 2 interventions - of which Test Product is the first listed.
NCT05370196 reports a single indexed study location in California.
Frequently Asked Questions
What is clinical trial NCT05370196 about?
NCT05370196 is a clinical study titled "Synthetic Male Condom Slippage-Breakage Study". This is a multi-site, double-blind, crossover, randomized phase II study to evaluate the functional performance of a synthetic male condom as compared to a marketed latex condom.
What is the current status of trial NCT05370196?
This trial is currently completed. It is a NA study. The enrollment target is 600 participants. The study started on 2022-06-10. Estimated completion is 2023-05-12.
What conditions does trial NCT05370196 study?
This clinical trial studies the following conditions: Sexually Transmitted Diseases, Contraceptive.
What interventions are being tested in trial NCT05370196?
The interventions under investigation include: Test Product (DEVICE), Control Product (DEVICE).
Who is sponsoring clinical trial NCT05370196?
This trial is sponsored by Church & Dwight Company, which has 19 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05370196 being conducted?
This trial has 2 study locations across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Sexually Transmitted Diseases
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05370196's enrollment target sits among peer trials
600 14th of 35 higher than 22 of 35 other Sexually Transmitted Diseases trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Sexually Transmitted Diseases trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Rigorous Evaluation of Yes and Know, a Fully Virtual Sexual Health and Well-Being Intervention for Youth
RECRUITING · NA
-
Evaluation of Parent Toolkit 2.0 (Morehouse Family Health Study)
RECRUITING · NA
-
Health Information Technology to Reduce Disparities in Adolescent Health Outcomes: A Pragmatic Trial
RECRUITING · NA
-
Using Mobile Health (mHealth) to Improve STI Treatment Adherence Among Adolescents
RECRUITING · NA
-
Comparing Mobile Health Strategies to Improve Pre-exposure Prophylaxis Use (PrEP) for HIV Prevention
RECRUITING · NA
-
Improving Alcohol and Substance Use Care Access, Outcome, Equity During the Reproductive Years
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00004317 · 600 participants · Phase 4
Pyrimethamine, Sulfadiazine, and Leucovorin in Treating Patients With Congenital Toxoplasmosis
- NCT00209235 · 600 participants · NA
Albright Hereditary Osteodystrophy: Natural History, Growth, and Cognitive/Behavioral Assessments
- NCT01473784 · 600 participants · NA
Transoral Robotic Surgery in Treating Patients With Benign or Malignant Tumors of the Head and Neck
- NCT01866371 · 600 participants
High Resolution Retinal Imaging
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI